Prof. Rossing talks about setting treatment goals for patients with T2DM and CKD. These treatment goals are not limited to risk factor control but are also focused on organ protection.
Subtitles: English, French, German & more
This lecture by Prof. Peter Rossing was part of the EBAC-accredited symposium "SGLT2i in CKD: How to overcome clinical inertia?" held during the virtual ERA EDTA 2021 congress.
Prof. Peter Rossing is head of research and chief physician at the Steno Diabetes Center in Copenhagen, Denmark.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim and Lilly.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- SGLT2i in CKD: How to overcome clinical inertia?Practical challenges with SGLT2i therapy in patients with T2DM and CKD
Alice Cheng, MD
- SGLT2i in CKD: How to overcome clinical inertia?Clinical inertia in CKD - What is the rationale for SGLT2i?
Janaka Karalliedde, MD, PhD